We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Novopharm Limited v. Eli Lilly and Company (2010 FC 915)
  • Gowling WLG
  • Canada
  • October 27 2010

An impeachment action was brought by Novopharm in respect of a patent for STRATTERA alleging obviousness, anticipation, utility and improper selection


Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness


Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case
  • Gowling WLG
  • Canada
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record


Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)
  • Gowling WLG
  • Canada
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998


Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope
  • Gowling WLG
  • Canada, United Kingdom
  • October 13 2011

Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL


Purdue Pharma v Minister of Health, judicial review of decision of Office of Patented Medicines and Lliaison (“OPML”), TARGIN, July 8, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Purdue filed a New Drug Submission ("NDS") as part of its application for a notice of compliance ("NOC") to market and sell the drug TARGIN in Canada


Novo Nordisk v. Cobalt Pharmaceuticals, S. 55.2 proceeding, Repaglinide, Aug. 3, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Cobalt served a NOA with respect to repaglinide, the S enantiomer of a previously disclosed racemic compound (the “388 compound”), alleging invalidity of the '851 patent on grounds of anticipation, obviousness and s. 53(1


Sandoz Canada v Abbott Laboratories, appeal and cross-appeal of PMNOC decision, Clarithromycin extended-release, June 22, 2010
  • Gowling WLG
  • Canada
  • August 26 2010

Sandoz served a notice of allegation ("NOA") upon Abbott and filed an Abbreviated New Drug Submission ("ANDS") with respect to clarithromycin extended-release


Merck-Frosst-Schering Pharma GP v. Canada (Health) (2010 FC 933)
  • Gowling WLG
  • Canada
  • October 27 2010

Merck-Frosst (“Merck”) applied for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Teva for its generic version of Ezetimibe